Stellantis Trails Its Rival on Key Metrics but Offers Compelling Upside for Patient Investors

Stellantis shares are down nearly 47% over the past year despite GM gaining 47%, reflecting severe fundamentals: 2025 revenue fell 2.1% and net income swung to a €22.4B ($25.6B) loss (vs. €5.5B profit in 2024). The company suspended its dividend, but Q1 2026 sales rose 6.4% and EPS of €0.14 ($0.16) beat expectations as turnaround efforts get underway. If 2027 earnings of $0.85 and $1.76 in 2028 materialize, the stock trading around $5.30 could rebound toward double-digit price levels over time.

Analysis

STLA is still priced like a balance-sheet and execution risk story, not a normal cyclical auto name. The market will only pay up if the turnaround shows up in cash generation, because auto EPS can rebound mechanically while free cash flow stays weak from incentives, inventory, and capex. That means the rerating path is less about one quarter of profit and more about 2-3 consecutive prints of margin discipline and working-capital control.

Relative winners are the peers with cleaner capital return visibility and less need to “prove” a turnaround; GM already has that premium, while F looks like the lower-quality U.S. cyclical if pricing stays soft. A successful STLA reset would pressure weaker suppliers and dealer inventory chains, because the fastest lever is usually SKU rationalization and tougher purchasing terms, not volume growth. That can lift gross margin at STLA but compress revenue quality across the ecosystem.

The key risk is that 2027 consensus embeds a smoother recovery than autos usually deliver when rates stay elevated and tariffs/inflation distort affordability. If management does not convert early sales stabilization into sustained FCF, the stock likely stays in single digits and could revisit the low-$4s on any guidance miss. Conversely, if the company confirms sequential EBIT improvement and no dividend-capital allocation missteps, a move into the high-$7s or low-$8s is plausible before any full mid-cycle rerating.

The contrarian miss is that investors may focus too much on headline EPS normalization and too little on the quality of the recovery. In autos, a credible turnaround is usually rewarded only when it looks durable, not when it is merely cheap. That makes STLA interesting as a defined-risk optionality play, but not yet as a high-conviction outright long.

Key Decisions for Investors

• Pair trade: long GM / short STLA for 1-3 months, expecting the market to keep paying for quality capital returns while STLA still needs proof of FCF durability; target 10-15% relative outperformance, stop if STLA raises guidance or reinstates capital returns sooner than expected.
• If expressing upside in STLA, prefer a defined-risk structure: buy 6-12 month call spreads centered above the current stock price rather than stock outright, since the thesis depends on a multi-quarter execution path and the downside remains value-trap risk.
• Set a watch item on the next 2 quarterly prints for STLA free cash flow, sequential EBIT margin, and inventory trends; if those do not improve, treat the turnaround as falsified and avoid adding on weakness.
• Stay underweight F versus GM on a relative basis while rates and affordability remain pressured; GM has already earned a quality premium, and F is more exposed to a prolonged demand normalization than the market is likely pricing.